Skip to main content

Table 2 Overall Survival by ESR1 PvuII polymorphism alleles

From: ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer

Group

No.

Events

OS, Median (95% CI), days

Hazard Ratio (95% CI)

P-value

TT variant

44

22

1375 (965–1784)

NA

 

TC variant

41

28

730 (237–1222)

1.77 (1.01–3.1)

0.046

CC variant

19

10

644 (601–686)

1.85 (0.85–4.01)

0.117

TC + CC variants

60

34

654 (449–858)

1.79 (1.05–3.04)

0.032

  1. Abbreviation: NA not applicable
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us